Novartis Q3 Results Lift Outlook Despite $1.9B Drug Hit

Novartis raises its annual core-profit outlook as priority medicines grow, while a US$1.9 billion del-desiran write-down helps drive a sharp fall in reported earnings.

BullBuzz Writer • 2026-10-27T12:29:16.000Z

Novartis Q3 results: Novartis sign in the Reuters photograph accompanying its earnings report

Novartis Q3 results brought a higher annual core-profit outlook alongside a US$1.9 billion partial write-down tied to an experimental medicine. The Swiss drugmaker announced the figures on Tuesday, 27 October MYT, as growing sales of priority brands offset pressure from generic competition.

In its official earnings announcement, Novartis raised its full-year core operating income forecast to broadly unchanged or low single-digit growth at constant currencies. It had previously expected a low single-digit decline. Its low single-digit sales-growth outlook was unchanged.

The upgrade concerns an adjusted earnings measure. Reported operating income and net income both fell sharply during the quarter, making the distinction between the underlying outlook and the accounting result central to reading the announcement.

Novartis Q3 Results Separate Core and Reported Profit

The company's interim financial report records quarterly net sales of US$14.522 billion, up 4% in dollars. Core operating income rose 11% in dollars to US$6.036 billion, or 10% after removing currency effects.

Reported operating income fell 59% in dollars to US$1.843 billion, while net income declined 70% to US$1.196 billion. Higher research and development costs, including the write-down, and other expenses weighed on those reported figures.

  • Core operating margin: 41.6% of net sales.
  • Reported operating margin: 12.7%.
  • Core earnings per share: US$2.46.
  • Reported earnings per share: US$0.63.

These pairs describe different measures of the same quarter. Using the core margin beside reported earnings without explaining the adjustments would obscure the size of the gap. Investors can check the reconciliation supplied with the company's financial statements.

Constant-currency comparisons remove the effect of translating sales and earnings between currencies. They help readers compare operating trends across periods, while the dollar figures remain the amounts presented in the accounts. A forecast expressed at constant currencies should be evaluated on that same basis when subsequent results arrive.

Drug-Development Setback Drives the Write-Down

Reuters reported that the del-desiran charge followed a late-stage trial setback disclosed in September. The treatment had been obtained through the Avidity acquisition. The charge reduced the accounting value assigned to the asset; it was not a newly announced acquisition payment.

The financial report says the impairment reduced del-desiran's carrying amount to US$5.5 billion. Novartis is assessing the trial dataset and expects to discuss the development path with health authorities. Continued development remains subject to uncertainty.

Reuters also reported a separate US$300 million charge involving pelacarsen. Those pipeline setbacks place the stronger commercial performance alongside risks inherent in buying and developing medicines whose future sales depend on successful studies and regulatory decisions.

Established Brands Support the Improved Outlook

Investing.com reported that stronger demand for key medicines and newer products supported the outlook upgrade. Sales growth at constant currencies included 37% for Kisqali, 22% for Kesimpta and 67% for Scemblix.

Generic competition remains a counterweight. The company said stronger volumes were partly offset by that competition, while pricing also reduced sales growth. The improved outlook therefore depends on growth products continuing to replace revenue lost elsewhere in the portfolio.

For readers comparing this earnings season, BullBuzz's HSBC quarterly-results report also distinguishes reported from adjusted performance. The Infosys guidance coverage illustrates a separate outlook revision in another industry. Neither comparison implies that the companies face identical risks.

What Shareholders Should Watch Next

The next checks are delivery against the upgraded core-income forecast, cash generation and further pipeline disclosures. A better adjusted outlook does not reverse the loss already recognised in the accounts or establish that a delayed medicine will reach the market.

For Malaysian investors following overseas healthcare shares, this is a company earnings development. The release does not announce Malaysian approval, availability or pricing for the medicines discussed. Future financial and regulatory disclosures should be assessed separately, using the relevant reporting basis and jurisdiction.

Article information

Published • Updated

Explore BullBuzz